Dlin-MC3-DMA: Benchmark Ionizable Lipid for Lipid Nanoparticle siRNA & mRNA Delivery

Executive Summary: Dlin-MC3-DMA (DLin-MC3-DMA, CAS No. 1224606-06-7) is an ionizable cationic liposome lipid enabling efficient in vivo lipid nanoparticle (LNP) siRNA and mRNA delivery, particularly for hepatic gene silencing and immunomodulatory applications (Rafiei et al. 2025). It achieves ~1000-fold greater potency than its precursor DLin-DMA in murine gene silencing models. Dlin-MC3-DMA is neutral at physiological pH, reducing toxicity, but protonates at acidic pH to facilitate endosomal escape (APExBIO). It is a core component of clinically relevant LNPs for advanced gene therapy, cancer immunochemotherapy, and mRNA vaccine formulation. Storage, solubility, and workflow parameters are well-documented, ensuring reproducible results in research and translational settings.

Biological Rationale

Dlin-MC3-DMA is a synthetic ionizable cationic lipid designed to address the delivery challenges of nucleic acid therapeutics. Its ability to switch charge states under different pH conditions underlies its function as a lipid nanoparticle siRNA delivery vehicle. At physiological pH (~7.4), Dlin-MC3-DMA remains largely neutral, minimizing systemic toxicity and non-specific interactions (Rafiei et al. 2025). Upon encountering the acidic endosomal environment (pH 5–6), Dlin-MC3-DMA becomes protonated, acquiring a positive charge that disrupts the endosomal membrane and releases nucleic acids into the cytoplasm. This endosomal escape mechanism is essential for efficient gene silencing and mRNA delivery in vivo (see molecular mechanisms—this article extends the mechanistic detail on endosomal escape strategies over prior summaries).

Dlin-MC3-DMA is a central component in LNP formulations alongside phosphatidylcholine (DSPC), cholesterol, and PEGylated lipids (e.g., PEG-DMG). This composition enables high encapsulation efficiency, stability, and tissue-specific delivery—a critical advancement for mRNA vaccine and gene therapy platforms (see advanced design strategies—here we detail the performance benchmarks in disease models).

Mechanism of Action of Dlin-MC3-DMA (DLin-MC3-DMA, CAS No. 1224606-06-7)

Dlin-MC3-DMA mediates nucleic acid delivery through its pH-sensitive ionizable headgroup. At physiological pH, its neutral charge profile allows LNPs to circulate in the bloodstream with low immunogenicity and reduced off-target effects. Following cellular uptake via endocytosis, the acidic endosomal pH triggers protonation of the dimethylamino group, converting Dlin-MC3-DMA into a cationic species. This promotes electrostatic interactions with anionic phospholipids in the endosomal membrane, leading to membrane destabilization and endosomal escape (Rafiei et al. 2025). Released siRNA or mRNA reaches the cytoplasm, where it can induce RNA interference or translation, respectively. This mechanism is fundamental for successful hepatic gene silencing and mRNA-based immunomodulation (see atomic mechanisms—this article benchmarks the specific efficacy of Dlin-MC3-DMA).

The high potency of Dlin-MC3-DMA is attributed to its optimized pKa (~6.44), which balances efficient endosomal escape with low systemic toxicity. This property distinguishes it from earlier ionizable lipids, such as DLin-DMA, which exhibited limited in vivo efficacy due to suboptimal endosomal release (APExBIO).

Evidence & Benchmarks

• Dlin-MC3-DMA exhibits approximately 1000-fold greater potency in hepatic gene silencing compared to DLin-DMA in mice (ED₅₀ for Factor VII silencing: 0.005 mg/kg) (Rafiei et al. 2025).
• In non-human primates, Dlin-MC3-DMA achieves transthyretin (TTR) gene silencing at ED₅₀ of 0.03 mg/kg, supporting translational relevance (Rafiei et al. 2025).
• Solubility: Dlin-MC3-DMA is insoluble in water and DMSO but dissolves in ethanol ≥152.6 mg/mL at ambient temperature (APExBIO).
• In mRNA delivery to LPS-activated BV-2 murine microglia, Dlin-MC3-DMA-based LNPs achieved high transfection efficiency and immunomodulation, as validated with ML-guided morphometric analysis (Rafiei et al. 2025).
• Storage at −20°C or below preserves stability for ≥6 months; ethanol solutions should be used promptly to avoid degradation (APExBIO).

Applications, Limits & Misconceptions

Dlin-MC3-DMA underpins next-generation lipid nanoparticle-mediated gene silencing and mRNA drug delivery, with proven efficacy in hepatic gene silencing, mRNA vaccine formulation, and immunomodulatory therapies (Rafiei et al. 2025). Its ionizable cationic profile enables high payload encapsulation and targeted release, making it central to cancer immunochemotherapy studies and precision gene therapy approaches.

Compared to earlier cationic lipids, Dlin-MC3-DMA's improved safety and potency have enabled translation from preclinical to clinical applications. However, its effectiveness depends on careful formulation with helper lipids and precise control of physicochemical parameters (see laboratory workflow—this article quantifies benchmark potency and ML-guided optimization).

Common Pitfalls or Misconceptions

• Non-aqueous solubility: Dlin-MC3-DMA is not soluble in water or DMSO; improper solvent use leads to precipitation and reduced efficacy (APExBIO).
• pH-dependent activity: Activity relies on endosomal acidification; it is ineffective in non-endocytosing systems.
• Not a universal LNP lipid: Dlin-MC3-DMA is optimized for siRNA/mRNA; it is not validated for DNA or protein delivery.
• Degradation upon storage: Ethanol solutions degrade if stored above −20°C or for prolonged periods.
• Over-reliance on charge: Potency also depends on helper lipid ratios, not solely on cationic character.

Workflow Integration & Parameters

For optimal results, Dlin-MC3-DMA is typically combined in a molar ratio of 50:10:38.5:1.5 (Dlin-MC3-DMA:DSPC:cholesterol:PEG-DMG) for LNP formation. The ethanol-dissolved lipid mixture should be rapidly combined with an aqueous nucleic acid solution to promote spontaneous nanoparticle assembly. Particle size (typically 80–120 nm), polydispersity index, and encapsulation efficiency should be characterized by DLS and HPLC. N/P ratio (lipid to nucleic acid phosphate) is tuned for payload and cell type, with ratios between 6:1 and 12:1 common for siRNA delivery (Rafiei et al. 2025).

Store the A8791 kit (Dlin-MC3-DMA, CAS No. 1224606-06-7) at −20°C or lower; prepare fresh ethanolic solutions for each experiment (product details). For broader context, this review uniquely analyzes ML-guided LNP design and compares it to the present evidence-based benchmarks.

Conclusion & Outlook

Dlin-MC3-DMA has become a gold-standard ionizable cationic liposome for lipid nanoparticle-mediated gene silencing and mRNA delivery. Its unique pH-responsive profile enables potent, low-toxicity delivery of nucleic acids in preclinical and emerging clinical settings. As demonstrated in recent machine learning-guided studies, Dlin-MC3-DMA is central to the next generation of precision mRNA vaccine, immunotherapy, and gene therapy platforms (Rafiei et al. 2025). For reproducible results and translational success, adherence to formulation, storage, and workflow parameters is essential. Researchers can source validated Dlin-MC3-DMA from APExBIO for benchmark performance in LNP-based applications.